Site Search Results
Search returned 7 results.
-
Pilot Study of Medication Adherence in Children, Adolescents, and Adults with Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials
Open - RecruitingNCI Protocol ID NCI-18-C-0093Investigator Staci Martin Peron, Ph.D.Share this trial: Referral ContactsContact Name Phone Number Andrea Gross (link sends e-mail) 240.858.3853 -
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals with Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)
Open - RecruitingNCI Protocol ID NCI-15-C-0195Investigator Pamela L. Wolters, Ph.D.Share this trial: Referral ContactsContact Name Phone Number Pamela Wolters (link sends e-mail) 240.760.6035 -
Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults with Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (cNF)
Open - RecruitingNCI Protocol ID NCI-18-C-0102Investigator Andrea M. Gross, M.D.Share this trial: Referral ContactsContact Name Phone Number Katie McHugh (link sends e-mail) 240.858.3377 -
Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Open - RecruitingNCI Protocol ID NCI-16-C-0043Investigator Brigitte C. Widemann, M.D.Share this trial: Referral ContactsContact Name Phone Number Anne Goodwin (link sends e-mail) 240-760-6195 -
A Phase I/II Study of the Cyclin-Dependent Kinase(CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type 1 (NF1) Related Atypical Neurofibromas
Open - Not yet RecruitingNCI Protocol ID NCI-21-C-0011Investigator Andrea M. Gross, M.D.Share this trial: Referral ContactsContact Name Phone Number Anne Goodwin (link sends e-mail) 240.760.6195 -
Phase I/II Trial of PLX3397 in Children and Young Adults with Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
Open - RecruitingNCI Protocol ID NCI-15-C-0093Investigator Rosandra N. Kaplan, M.D.Share this trial: Referral ContactsContact Name Phone Number Melissa Spencer (link sends e-mail) 240.760.6101 -
A Phase 2 Trial of The MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Open - RecruitingNCI Protocol ID NCI-19-C-0061Investigator Brigitte C. Widemann, M.D.Share this trial: Referral ContactsContact Name Phone Number Anne Goodwin (link sends e-mail) 240.760.6195